About US
Contact us
-
GSK whistleblower claims to have been fired after emailing CEO about Nicoderm concernsGlaxoSmithKline's ($GSK) Nicoderm products are among the leaders in helping smokers kick their habits. But a former employeesays the study that showed their edge over competitors was flawed and that h2016/1/11
-
U.K. investor Woodford calls again for breakup of 'complicated' GSKIn October, high-profile U.K. fund managerNeil Woodfordadvocated for a four-way breakup of GlaxoSmithKline ($GSK), a company he said could unlock "significant shareholder value" by splitting apart. An2016/1/11
-
FDA not satisfied with Cadila's efforts to fix warfarin production, even after 15 responsesCadila Healthcarelast week got out in front of bad news by announcing it had received a warning letter from theFDAfor two of its Indian plants but was doing all that was asked by the agency. What it d2016/1/8
-
Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conferenceThere are big questions facing some of pharma's key players this year, like whether the Pfizer ($PFE) and Allergan ($AGN) deal will get done and why Allergan thinks that is its best route. Or what Myl2016/1/8
-
CEO Frazier expects Merck to be player in hep C market, M&A this yearMerck & Co.'s ($MRK) CEOKenneth Frazierexpects his company to be a player in the lucrative hepatitis C market again with the anticipated approval this month of its hep C candidate. That, along wit2016/1/7
-
Novartis, not to be outdone by respiratory rivals, inks 'smart inhaler' dealRespiratory drugmakers have been looking to "smart inhaler" technology to give them a leg up on marketing in a crowded field. And Novartis ($NVS) wants a part of it. TheSwiss drugmaker is collaboratin2016/1/7
-
Takeda snatches Baxalta plant to produce Entyvio in U.S.Takeda Pharmaceutical CEOChristophe Weberis in the midst of crafting the Japanese company's turnaround, and a piece of that effort isEntyvio, a drug he says should chip in $2 billion at its peak. Webe2016/1/6
-
No M&A? No problem, Actelion says as it rolls out $160K-plus UptraviActelion ($ATLN) predicts it'll have a difficult time competing against its rivals for M&A targets going forward. But never fear. The company will have plenty to plow into its own development work2016/1/6
-
FDA grants orphan drug status for GBT's once-daily therapy to treat sickle cell diseaseThe US Food and Drug Administration (FDA) has granted orphan drug designation for Global Blood Therapeutics' (GBT) once-daily therapy GBT440 to treat patients with sickle cell disease (SCD), an inheri2016/1/5
-
Lixte licenses lead cancer compound to Taipei Medical University for new HCC treatmentUS-based Lixte Biotechnology Holdings has granted an exclusive licence of its lead anti-cancer compound, LB-100, to Taipei Medical University (TMU). The compound will be used to develop new treatment2016/1/5